FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 760 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Mom Diagnosed With Breast Cancer Adopts Healthy Lifestyle To Reinvent Her... November 7, 2021 FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma March 12, 2021 New chemotherapy-free treatment for bowel cancer made available in Scotland September 14, 2021 A Personalised Prediction Model Based on Clinical and Genomic Data Outperforms... September 2, 2021 Load more HOT NEWS Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD... Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination... Cancer Research UK announces appointment of new Chair
